Explore
Validate
Learn
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [2]
- Comments [0]
- Validations
- Western blot [1]
- Immunohistochemistry [1]
- Other assay [3]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PA5-40961 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- TRIM31 Polyclonal Antibody
- Antibody type
- Polyclonal
- Antigen
- Synthetic peptide
- Description
- Peptide sequence: CRESKDHKSH NVSLIEEAAQ NYQGQIQEQI QVLQQKEKET VQVKAQGVHR
- Concentration
- 0.5 mg/mL
Submitted references The E3 ubiquitin-protein ligase Trim31 alleviates non-alcoholic fatty liver disease by targeting Rhbdf2 in mouse hepatocytes.
TRIM31 inhibits NLRP3 inflammasome and pyroptosis of retinal pigment epithelial cells through ubiquitination of NLRP3.
Xu M, Tan J, Dong W, Zou B, Teng X, Zhu L, Ge C, Dai X, Kuang Q, Zhong S, Lai L, Yi C, Tang T, Zhao J, Wang L, Liu J, Wei H, Sun Y, Yang Q, Li Q, Lou D, Hu L, Liu X, Kuang G, Luo J, Xiong M, Feng J, Zhang C, Wang B
Nature communications 2022 Feb 25;13(1):1052
Nature communications 2022 Feb 25;13(1):1052
TRIM31 inhibits NLRP3 inflammasome and pyroptosis of retinal pigment epithelial cells through ubiquitination of NLRP3.
Huang P, Liu W, Chen J, Hu Y, Wang Y, Sun J, Feng J
Cell biology international 2020 Nov;44(11):2213-2219
Cell biology international 2020 Nov;44(11):2213-2219
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis of human Jurkat cell lysate using an anti-TRIM31 polyclonal antibody (Product # PA5-40961).
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemistry analysis of human kidney tissue using an anti-TRIM31 polyclonal antibody (Product # PA5-40961).
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- 2 Figure Effect of TRIM31 overexpression on ox-LDL-treated ARPE-19 cells. (a) ARPE-19 cells were transfected with vector or plasmid overexpressing TRIM31 (oeTRIM31) for 48 hr. Western blot analysis was conducted to detect TRIM31. *** p < .001 as compared with the vector group. (b-d) ARPE-19 cells were transfected with vector or oeTRIM31 in the presence of 200 mug/mL ox-LDL for 48 hr. Cells in the control group had no treatment. (b) Cell pyroptosis was tested using double staining of activated caspase-1 and PI. (c) Western blot analysis of NLRP3, IL-1beta, pro-IL-1beta, caspase-1, and procaspase-1. (d) ELISA showing the concentration of IL-1beta in the supernatant. Values represent the mean +- standard deviation ( n = 5). ** p < .01, *** p < .001 as compared with the control group; ## p < .01, ### p < .001 as compared with the vector group. ELISA, enzyme-linked immunosorbent assay; IL-1beta, interleukin-1beta; ox-LDL, oxidized low-density lipoprotein; PI, propidium iodide
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- 3 Figure Effect of TRIM31 knockdown and NLRP3 inhibition on IL-1beta and caspase-1 in ARPE-19 cells. (a) ARPE-19 cells were transfected with control siRNA (siNC) or TRIM31 siRNA (siTRIM31#1, #2 or #3) for 48 hr. Western blot analysis was conducted to detect TRIM31. Values represent the mean +- standard deviation ( n = 3). * p < .05, ** p < .01, *** p < .001 as compared with the siNC group. (b-d) ARPE-19 cells were transfected with siNC or TRIM31 siRNA (siTRIM31#2) in the presence of 10 muM INF39/DMSO (vehicle) for 48 hr. (b) Cell pyroptosis was tested using double staining of activated caspase-1 and PI. (c) Western blot analysis of NLRP3, IL-1beta, pro-IL-1beta, caspase-1, and procaspase-1. (d) ELISA showing the concentration of IL-1beta in the supernatant. Values represent the mean +- standard deviation ( n = 5). ** p < .01, *** p < .001 as compared with the siNC group; # p < .05, ## p < .01 as compared with the siTRIM31#1+vehicle group; $$ p < .01 as compared with the siTRIM31#2+vehicle group; ++ p < .01 as compared with the siTRIM31#3+vehicle group. DMSO, dimethyl sulfoxide; ELISA, enzyme-linked immunosorbent assay; IL-1beta, interleukin-1beta; ox-LDL, oxidized low-density lipoprotein; PI, propidium iodide; siRNA, small interfering RNA
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- 4 Figure Effect of TRIM31 overexpression on NLRP3 ubiquitination. (a) Confirmation of the interactions between TRIM31 and NLRP3 by coimmunoprecipitation and western blot analysis in human RPE cells. (b) ARPE-19 cells were transfected with vector or plasmid overexpressing TRIM31 (oeTRIM31) for 48 hr and subjected to immunoprecipitation experiments. Anti-ubiquitin (Ub) detected NLRP3 ubiquitination in each group. IgG, immunoglobulin G; RPE, retinal pigment epithelial
